Carl Zeiss Meditec AG

  • WKN: 531370
  • ISIN: DE0005313704
  • Land: Deutschland

Nachricht vom 02.10.2019 | 09:13

Carl Zeiss Meditec AG achieves significant growth in revenue and profit in fiscal year 2018/19

Carl Zeiss Meditec AG / Key word(s): Annual Results
Carl Zeiss Meditec AG achieves significant growth in revenue and profit in fiscal year 2018/19

02-Oct-2019 / 09:13 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Carl Zeiss Meditec AG achieves significant growth in revenue and profit in fiscal year 2018/19

Jena, October 2, 2019

Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of approximately EUR 1,459 million in fiscal year 2018/19 (PY: EUR 1,280.9 million), based on preliminary data, and has thereby significantly exceeded the previous forecast of EUR 1,350 to EUR 1,420 million. This corresponds to revenue growth of approximately 13.9% vs. the previous year's value. After adjustment for currency effects[1], growth amounts to around 11.9 %.

From today's point of view, the company expects a strong increase in operating earnings[2] (EBIT) and anticipates to significantly exceed the previous forecast of an EBIT margin[3] between 15.0% to 17.5% (PY: 15.4%) as well as current market expectations estimated at around 18.5%.

Full results for business year 2018/19 will be provided on Dec 6, 2019.

As already reported after nine months 2018/19, management expects no further sustainable increase in EBIT margin in fiscal year 2019/20, partly due to planned strategic investments in research and development.
 
 

Contact for investors and press
Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Tel.: +49 3641 220-116
E-Mail: investors.meditec@zeiss.com

[1] Currency-adjusted sales growth is determined by weighing sales in the comparative period with current instead of actual historical exchange rates.
[2] Earnings before interest and taxes (also operating profit, EBIT) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated in accordance with IFRS standards (see Annual Report 2017/18, p. 76 for reconciliation).
[3] Calculation: EBIT margin = EBIT / revenue (in %) (see Annual Report 2017/18, p. 76).


02-Oct-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Event im Fokus

Fachkonferenz Beteiligungsgesellschaften, 15.07.2020

Fachkonferenz Consumer / Leisure, 16.07.2020

Die Konferenzen finden aufgrund der aktuellen Situation nicht in den Räumen der Börse München statt, sondern als Online-Konferenz.

GBC-Fokusbox

Anleihe der German Real Estate Capital S.A. stark überdurchschnittlich attraktiv

Die Anleihe der German Real Estate Capital S.A. weist aktuell eine Effektivverzinsung von ca. 14 % auf. Da es sich hier quasi um eine Immobilien-Anleihe handelt, ist das Anleiherisiko überschaubar. Insgesamt verfügt die German Real Estate-Gruppe über 6 Objekte, 24 Bestands- und 22 Handelsobjekte, womit eine Kombination aus stetigen Einnahmen und attraktiven Entwicklerrenditen erreicht wird. Wir stufen die Anleihe als stark überdurchschnittlich attraktiv ein.